Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joseph O. Deasy is active.

Publication


Featured researches published by Joseph O. Deasy.


International Journal of Radiation Oncology Biology Physics | 2001

A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results☆

K.S.Clifford Chao; Joseph O. Deasy; Jerry Markman; Joyce Haynie; Carlos A. Perez; James A. Purdy; Daniel A. Low

OBJECTIVES In a prospective clinical study, we tested the hypothesis that sparing the parotid glands may result in significant objective and subjective improvement of xerostomia in patients with head-and-neck cancers. The functional outcome 6 months after the completion of radiation therapy is presented. METHODS AND MATERIALS From February 1997 to February 1999, 41 patients with head-and-neck cancers were enrolled in a prospective salivary function study. Inverse-planning intensity-modulated radiation therapy (IMRT) was used to treat 27 patients, and forward-planning three-dimensional radiation therapy in 14. To avoid potential bias in data interpretation, only patients whose submandibular glands received greater than 50 Gy were eligible. Attempts were made to spare the superficial lobe of the parotid glands to avoid underdosing tumor targets in the parapharyngeal space; however, the entire parotid volume was used to compute dose-volume histograms (DVHs) for this analysis. DVHs were computed for each gland separately. Parotid function was assessed objectively by measuring stimulated and unstimulated saliva flow before and 6 months after the completion of radiation therapy. Measurements were converted to flow rate (mL/min) and normalized relative to that before treatment. The corresponding quality-of-life (QOL) outcome was assessed by five questions regarding the patients oral discomfort and eating/speaking problems. RESULTS We observed a correlation between parotid mean dose and the fractional reduction of stimulated saliva output at 6 months after the completion of radiation therapy. We further examined whether the functional outcome could be modeled as a function of dose. Two models were found to describe the dose-response data well. The first model assumed that each parotid gland is comprised of multiple independent parallel functional subunits (corresponding to computed tomography voxels) and that each gland contributes equally to overall flow, and that saliva output decreases exponentially as a quadratic function of irradiation dose to each voxel. The second approach uses the equivalent uniform dose (EUD) metrics, which assumes loss of salivary function with increase in EUD for each parotid gland independently. The analysis suggested that the mean dose to each parotid gland is a reasonable indicator for the functional outcome of each gland. The corresponding exponential coefficient was 0.0428/Gy (95% confidence interval: 0.01, 0.09). The QOL questions on eating/speaking function were significantly correlated with stimulated and unstimulated saliva flow at 6 months. In a multivariate analysis, a toxicity score derived from the model based on radiation dose to the parotid gland was found to be the sole significant predictive factor for xerostomia. Neither radiation technique (IMRT vs. non-IMRT) nor chemotherapy (yes or no) independently influenced the functional outcome of the salivary glands. CONCLUSION Sparing of the parotid glands translates into objective and subjective improvement of both xerostomia and QOL scores in patients with head-and-neck cancers receiving radiation therapy. Modeling results suggest an exponential relationship between saliva flow reduction and mean parotid dose for each gland. We found that the stimulated saliva flow at 6 months after treatment is reduced exponentially, for each gland independently, at a rate of approximately 4% per Gy of mean parotid dose.


International Journal of Radiation Oncology Biology Physics | 2010

Radiation Dose–Volume Effects in Radiation-Induced Rectal Injury

Jeff M. Michalski; Andrew Jackson; Susan L. Tucker; Joseph O. Deasy

The available dose/volume/outcome data for rectal injury were reviewed. The volume of rectum receiving >or=60 Gy is consistently associated with the risk of Grade >or=2 rectal toxicity or rectal bleeding. Parameters for the Lyman-Kutcher-Burman normal tissue complication probability model from four clinical series are remarkably consistent, suggesting that high doses are predominant in determining the risk of toxicity. The best overall estimates (95% confidence interval) of the Lyman-Kutcher-Burman model parameters are n = 0.09 (0.04-0.14); m = 0.13 (0.10-0.17); and TD(50) = 76.9 (73.7-80.1) Gy. Most of the models of late radiation toxicity come from three-dimensional conformal radiotherapy dose-escalation studies of early-stage prostate cancer. It is possible that intensity-modulated radiotherapy or proton beam dose distributions require modification of these models because of the inherent differences in low and intermediate dose distributions.


International Journal of Radiation Oncology Biology Physics | 2010

Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): An Introduction to the Scientific Issues

Søren M. Bentzen; Louis S. Constine; Joseph O. Deasy; A. Eisbruch; Andrew Jackson; Lawrence B. Marks; Randall K. Ten Haken; Ellen Yorke

Advances in dose-volume/outcome (or normal tissue complication probability, NTCP) modeling since the seminal Emami paper from 1991 are reviewed. There has been some progress with an increasing number of studies on large patient samples with three-dimensional dosimetry. Nevertheless, NTCP models are not ideal. Issues related to the grading of side effects, selection of appropriate statistical methods, testing of internal and external model validity, and quantification of predictive power and statistical uncertainty, all limit the usefulness of much of the published literature. Synthesis (meta-analysis) of data from multiple studies is often impossible because of suboptimal primary analysis, insufficient reporting and variations in the models and predictors analyzed. Clinical limitations to the current knowledge base include the need for more data on the effect of patient-related cofactors, interactions between dose distribution and cytotoxic or molecular targeted agents, and the effect of dose fractions and overall treatment time in relation to nonuniform dose distributions. Research priorities for the next 5-10 years are proposed.


Pattern Recognition | 2009

Exploring feature-based approaches in PET images for predicting cancer treatment outcomes

I. El Naqa; Perry W. Grigsby; A Apte; Elizabeth A. Kidd; Eric D. Donnelly; D Khullar; S Chaudhari; Deshan Yang; M. Schmitt; Richard Laforest; Wade L. Thorstad; Joseph O. Deasy

Accumulating evidence suggests that characteristics of pre-treatment FDG-PET could be used as prognostic factors to predict outcomes in different cancer sites. Current risk analyses are limited to visual assessment or direct uptake value measurements. We are investigating intensity-volume histogram metrics and shape and texture features extracted from PET images to predict patients response to treatment. These approaches were demonstrated using datasets from cervix and head and neck cancers, where AUC of 0.76 and 1.0 were achieved, respectively. The preliminary results suggest that the proposed approaches could potentially provide better tools and discriminant power for utilizing functional imaging in clinical prognosis.


International Journal of Radiation Oncology Biology Physics | 2010

Radiotherapy Dose–Volume Effects on Salivary Gland Function

Joseph O. Deasy; Vitali Moiseenko; Lawrence B. Marks; K.S.Clifford Chao; Jiho Nam; Avraham Eisbruch

Publications relating parotid dose-volume characteristics to radiotherapy-induced salivary toxicity were reviewed. Late salivary dysfunction has been correlated to the mean parotid gland dose, with recovery occurring with time. Severe xerostomia (defined as long-term salivary function of <25% of baseline) is usually avoided if at least one parotid gland is spared to a mean dose of less than approximately 20 Gy or if both glands are spared to less than approximately 25 Gy (mean dose). For complex, partial-volume RT patterns (e.g., intensity-modulated radiotherapy), each parotid mean dose should be kept as low as possible, consistent with the desired clinical target volume coverage. A lower parotid mean dose usually results in better function. Submandibular gland sparing also significantly decreases the risk of xerostomia. The currently available predictive models are imprecise, and additional study is required to identify more accurate models of xerostomia risk.


Cancer Research | 2010

A MicroRNA Expression Signature for Cervical Cancer Prognosis

Xiaoxia Hu; Julie K. Schwarz; James S. Lewis; Phyllis C. Huettner; Janet S. Rader; Joseph O. Deasy; Perry W. Grigsby; Xiaowei Wang

Invasive cervical cancer is a leading cause of cancer death in women worldwide, resulting in about 300,000 deaths each year. The clinical outcomes of cervical cancer vary significantly and are difficult to predict. Thus, a method to reliably predict disease outcome would be important for individualized therapy by identifying patients with high risk of treatment failures before therapy. In this study, we have identified a microRNA (miRNA)-based signature for the prediction of cervical cancer survival. miRNAs are a newly identified family of small noncoding RNAs that are extensively involved in human cancers. Using an established PCR-based miRNA assay to analyze 102 cervical cancer samples, we identified miR-200a and miR-9 as two miRNAs that could predict patient survival. A logistic regression model was developed based on these two miRNAs and the prognostic value of the model was subsequently validated with independent cervical cancers. Furthermore, functional studies were done to characterize the effect of miRNAs in cervical cancer cells. Our results suggest that both miR-200a and miR-9 could play important regulatory roles in cervical cancer control. In particular, miR-200a is likely to affect the metastatic potential of cervical cancer cells by coordinate suppression of multiple genes controlling cell motility.


International Journal of Radiation Oncology Biology Physics | 2010

Radiation Dose-Volume Effects In the Esophagus

Maria Werner-Wasik; Ellen Yorke; Joseph O. Deasy; Jiho Nam; Lawrence B. Marks

Publications relating esophageal radiation toxicity to clinical variables and to quantitative dose and dose-volume measures derived from three-dimensional conformal radiotherapy for non-small-cell lung cancer are reviewed. A variety of clinical and dosimetric parameters have been associated with acute and late toxicity. Suggestions for future studies are presented.


International Journal of Radiation Oncology Biology Physics | 2010

The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome.

Andrew Jackson; Lawrence B. Marks; Søren M. Bentzen; Avraham Eisbruch; Ellen Yorke; Randal K. Ten Haken; Louis S. Constine; Joseph O. Deasy

The 16 clinical articles in this issue review the dose-volume dependence of toxicities of external beam radiotherapy. They are limited by the difficulty of synthesizing results from different publications. The major problems stem from incomplete reporting of results and use of incompatible or ambiguous endpoints. Here we specify these problems; give recommendations to authors, editors, and reviewers on standards of reporting; and provide methods of defining endpoints suitable for the dose-volume analysis of toxicity. Adopting these recommendations will facilitate meta-analysis and increase the utility of individual studies of the dependence of complications on dose distributions.


Medical Physics | 1997

An investigation of tomotherapy beam delivery

James N. Yang; T. Rock Mackie; Paul J. Reckwerdt; Joseph O. Deasy; Bruce R. Thomadsen

Experimental simulations for tomotherapy beam delivery were performed using a computer-controlled phantom positioner, a cylindrical phantom, and a 6 MV x-ray slit beam. Both continuous helical beam and sequential segmented tomotherapy (SST) beam deliveries were evaluated. Beam junctioning problem due to couch indexing error or field width errors presented severe dose uniformity perturbations for SST, while the problem was minimized for helical beam delivery. Longitudinal breathing motions were experimentally simulated for helical and SST beam delivery. While motions reduced the dose uniformity perturbations for SST, small artifacts in dose uniformity can be introduced for helical beam delivery. With typical breath frequency and magnitude, for a slit beam of 2.0 cm width at 4 rpm, the dose uniformity perturbation was not significant. A running start/stop technique was implemented with helical beam delivery to sharpen the 20%-80% longitudinal dose fall-off from 1.5 to 0.5 cm. The latter was comparable to the corresponding dose penumbra of a conventional 6 MV 10 x 10 cm2 field. All together, helical beam delivery showed advantages over SST for tomotherapy beam delivery under similar delivery conditions.


The Journal of Urology | 2012

Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era

Adam S. Kibel; Jay P. Ciezki; Eric A. Klein; C.A. Reddy; Jessica Lubahn; Jennifer Haslag-Minoff; Joseph O. Deasy; Jeff M. Michalski; Dorina Kallogjeri; Jay F. Piccirillo; Danny M. Rabah; Changhong Yu; Michael W. Kattan; Andrew J. Stephenson

PURPOSE Radical prostatectomy, external beam radiotherapy and brachytherapy are accepted treatments for localized prostate cancer. However, it is unknown if survival differences exist among treatments. We analyzed the survival of patients treated with these modalities according to contemporary standards. MATERIALS AND METHODS A total of 10,429 consecutive patients with localized prostate cancer treated with radical prostatectomy (6,485), external beam radiotherapy (2,264) or brachytherapy (1,680) were identified. Multivariable regression analyses were used to model the disease (biopsy grade, clinical stage, prostate specific antigen) and patient specific (age, ethnicity, comorbidity) parameters for overall survival and prostate cancer specific mortality. Propensity score analysis was used to adjust for differences in observed background characteristics. RESULTS The adjusted 10-year overall survival after radical prostatectomy, external beam radiotherapy and brachytherapy was 88.9%, 82.6% and 81.7%, respectively. Adjusted 10-year prostate cancer specific mortality was 1.8%, 2.9% and 2.3%, respectively. Using propensity score analysis, external beam radiotherapy was associated with decreased overall survival (HR 1.6, 95% CI 1.4-1.9, p<0.001) and increased prostate cancer specific mortality (HR 1.5, 95% CI 1.0-2.3, p=0.041) compared to radical prostatectomy. Brachytherapy was associated with decreased overall survival (HR 1.7, 95% CI 1.4-2.1, p<0.001) but not prostate cancer specific mortality (HR 1.3, 95% CI 0.7-2.4, p=0.5) compared to radical prostatectomy. CONCLUSIONS After adjusting for major confounders, radical prostatectomy was associated with a small but statistically significant improvement in overall and cancer specific survival. These survival differences may arise from an imbalance of confounders, differences in treatment related mortality and/or improved cancer control when radical prostatectomy is performed as initial therapy.

Collaboration


Dive into the Joseph O. Deasy's collaboration.

Top Co-Authors

Avatar

Jung Hun Oh

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

A. Apte

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Jeffrey D. Bradley

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

I. El Naqa

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Maria Thor

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Issam El Naqa

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

D Low

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

A Apte

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar

Andrew Jackson

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Ellen Yorke

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge